vTv Therapeutics Inc. announced that on July 11, 2022, the Board of Directors of the company, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed (i) Dr. Keith Harris as a member of the Board and a member and chair of the Audit Committee of the Board, effective immediately, and (ii) Dr. Fahed Al Marzooqi as a member of the Board, effectively immediately. Dr. Keith Harris and Dr. Fahed Al Marzooqi will each serve a term through the date of the next annual meeting of the Company's stockholders. As of the date hereof, Dr. Fahed Al Marzooqi has not been appointed to serve on any Committee of the Board.

Dr. Fahed Al Marzooqi was appointed to the Board pursuant to the previously announced common stock purchase agreement, dated as of May 31, 2022, between the Company, G42 Investments AI Holding RSC Ltd. and, solely for Sections 5.3, 5.11 and Section 6 therein, Group 42 Holding Limited. Dr. Keith Harris is a London-based investment banker and financier with a 30-year career as a senior corporate finance and takeover advisor, having held senior executive positions at leading institutions including Morgan Grenfell, Drexel Burnham Lambert, Apax Partners, and HSBC Investment Bank. Dr. Fahed Al Marzooqi is the Chief Operating Officer of G42 Healthcare, a position he has held since April 2021.

Dr. Fahed has over 15 years' experience with large and diverse organizations. Prior to joining G42 Healthcare, he was the Chief Administrative Officer at Cleveland Clinic Abu Dhabi, where he was an integral part of multiple high-impact strategic programs for the hospital.